Axol Bioscience, a biotech company with offices in Cambridge and Edinburgh, acquired Phenocell, a French company specializing in products for skin and retinal disorders. The acquisition adds to Axol’s portfolio of cell models, expanding into ophthalmology and dermatology.
Axol specializes in induced pluripotent stem cell, or iPSC, technology for drug discovery. It develops iPSC-derived cell models and services in research areas including neuroscience, pain and touch, and cardiovascular applications.
Phenocell’s expertise aids Axol in providing iPSC-based models for drug discovery and cosmetic sectors. This acquisition enables Axol to offer more consistent and relevant models and brings new cell models to Axol’s services, including human iPSC-derived sebocytes and retinal pigment epithelium and photoreceptor cells.
